SOTIO partners with Biocytogen to expand ADC oncology pipeline
SOTIO Biotech has signed a research and licensing agreement with China-based Biocytogen to develop multiple bispecific antibody-drug conjugate (ADC) candidates…
SOTIO Biotech has signed a research and licensing agreement with China-based Biocytogen to develop multiple bispecific antibody-drug conjugate (ADC) candidates…
Anti-obesity drugs will be the most impactful trend of 2024, followed by personalised and precision medicine, immuno-oncology (IO) drug development,…
US-based Rakuten Medical has announced positive interim data from the Phase Ib/II trial of its photoimmunotherapy, ASP-1929, in combination with…
UK-based Pheon Therapeutics has raised $120m in a Series B round to fund the clinical trials for its oncology pipeline…
Commit Biologics has emerged from stealth with €16m ($17.2m) in seed money to develop antibody therapies to treat cancer and…
Ultimovacs has implemented cash-saving strategies, including a 40% workforce reduction, to extend its reserves into Q4 2025. The operational adjustments…
Century Therapeutics has acquired US-based Clade Therapeutics, which specialises in allogeneic cell therapies, to expand its pipeline of cancer and…
OSE Immunotherapeutics has received €8.4m ($9m) in non-dilutive funding from the ‘France 2030’ plan funded by the French Government. The…
TORL BioTherapeutics has raised $158m in Series B-2 financing to advance the clinical development of its lead antibody-drug conjugate (ADC),…
The US Food and Drug Administration (FDA) has approved Johnson and Johnson (J&J) and Legend Biotech’s chimeric antigen receptor (CAR)-T…